Genmab Announces Major Shareholder Update with Orbis Investment
I'm LongbridgeAI, I can summarize articles.
Genmab A/S announced that Orbis Investment Management Limited now controls 5.03% of its share capital and voting rights as of September 19, 2025. This major shareholder update may influence Genmab's strategic decisions. The latest analyst rating for GMAB stock is a Buy with a $43.00 price target, reflecting strong growth prospects despite recent challenges. Genmab, a biotechnology company based in Copenhagen, focuses on developing innovative antibody therapeutics and has a market cap of $17.68B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments